52 citations,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
77 citations,
May 2012 in “Expert Opinion on Emerging Drugs” New treatments for male hypogonadism are effective and should be personalized.
65 citations,
March 1999 in “Urology” Finasteride didn't significantly improve ICPPS symptoms, more research needed.
27 citations,
August 1999 in “Urology” Finasteride improves urinary function in men for 2 years.
1 citations,
May 2017 in “Urologe A” Using tamsulosin and finasteride together for benign prostatic syndrome has increased and shows improvement in symptoms, but more reliable comparisons are needed.
12 citations,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
3 citations,
December 2014 in “Journal of Clinical Oncology” Men with a certain baldness pattern at age 40-50 may have a higher risk of aggressive prostate cancer.
33 citations,
October 2004 in “Archives of Dermatological Research” Large prostate links to more hair loss, but age of onset doesn't affect it.
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
49 citations,
August 2009 in “British Journal of Cancer” Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.
44 citations,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
14 citations,
December 1998 in “The Journal of Clinical Endocrinology and Metabolism” MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.
April 2012 in “The Journal of Urology” Male pattern baldness may predict prostate cancer risk.
April 2012 in “The Journal of Urology” Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.
September 2010 in “European Urology Supplements” Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.
September 2010 in “European Urology Supplements” The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.
September 2009 in “European Urology Supplements” Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.
147 citations,
June 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
72 citations,
April 2008 in “The Journal of urology/The journal of urology” Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
71 citations,
September 2007 in “Cancer” Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.
38 citations,
February 2011 in “Annals of Oncology” Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.
30 citations,
January 2008 in “The Aging Male” The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.
9 citations,
September 2014 in “Cancer Epidemiology, Biomarkers & Prevention” Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.
9 citations,
September 2010 in “Dermatologic Therapy” Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.
6 citations,
March 2015 in “Journal of Endocrinological Investigation” Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.
3 citations,
December 2016 in “Canadian Urological Association journal” Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.
2 citations,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
1 citations,
December 2017 in “Journal of The European Academy of Dermatology and Venereology” Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.
1 citations,
December 2013 in “Urological Science” A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.
August 2023 in “Malaysian Journal of Medicine and Health Sciences/Malaysian journal of medicine and health sciences” Pueraria mirifica extract may help treat benign prostatic hyperplasia.